FASEB SRC on HDACs, Sirtuins and Reversible Acetylation in Signaling and Disease

描述（由申请人提供）：组蛋白脱乙酰酶（HDAC）是基本细胞事件的重要调节因子，包括细胞周期进程、干细胞功能、细胞命运决定、细胞分化和许多疾病的发病机制。因此，蛋白质乙酰化是人类疾病的核心并不奇怪，如神经退行性疾病、心脏肥大、癌症、HIV感染以及更普遍的衰老过程。更重要的是，小分子HDAC抑制剂和激活剂目前正处于临床试验中，用于治疗白血病和淋巴瘤、实体瘤、神经肌肉疾病、代谢紊乱和其他疾病。此外，Sirtuins是HDAC的一个亚类，在酵母遗传研究中被认为是调节寿命的，这些酶可能是白藜芦醇的目标，白藜芦醇是红葡萄酒中与人类寿命延长有关的成分之一。因此，需要对HDAC进行彻底的了解，不仅是为了了解染色质结构，基因调控和蛋白质功能的调节，而且还因为HDAC密切参与了对人类健康产生重大影响的正常和异常细胞过程。在过去的十年中，随着18种人类HDACs（HDAC 1 - 11和SIRT 1 -7）和许多乙酰转移酶的鉴定，分离，克隆和功能表征，未来几年将看到我们对HDACs和蛋白质乙酰化的生物学作用的认识不断扩大。作为唯一一次专门针对这一领域的会议，这个一年两次的会议在汇集大约44名基础和临床科学家演讲者，与来自世界各地的大约120名参与者交流信息和开发新的治疗途径方面发挥着至关重要的作用。一个主要目标是在基础学术研究人员、临床科学家和制药科学家之间转移知识，以提高效率，了解他们如何控制人类健康，以及如何利用这些活动来对抗各种疾病。第二个目标是促进年轻调查员的发展和兴趣，以帮助支持他们的职业发展。为了实现这些目标，会议场地设有会议空间、餐厅和房间，以便与会者有充足的时间从正式演讲转向非正式的头脑风暴和协作讨论。此外，上午和晚上的口头报告会议包括从提交的摘要中选出的初级科学家的2-3次演讲，这对职业发展和鼓励下一代HDAC科学家很重要。将通过科学和社会计划强调创建一个全球HDAC社区。这次会议将特别及时，因为新一代HDAC和溴结构域药物的数据将被提交。因此，请求支持将于2013年8月18日至23日在意大利卢卡的Il Ciocco与FASEB联合举行的第四届关于HDAC和Sirtuins的生物学和治疗靶向及其在衰老和疾病中的作用的半年期会议。

DESCRIPTION (provided by applicant): Histone deacetylases (HDACs) are vital regulators of fundamental cellular events, including cell cycle progression, stem cell functions, cell fate determination, cell differentiation, and the pathogenesis of many diseases. As such, it is not surprising that protein acetylation is central to human diseases, as diverse as neurodegenerative disorders, cardiac hypertrophy, cancer, HIV infection, and more generally the process of aging. More importantly, small molecule HDAC inhibitors and activators are currently in clinical trials for the treatment of leukemia and lymphoma, solid tumors, neuromuscular disorders, metabolic disorders and other diseases. In addition, the Sirtuins, a subclass of HDACs, were fingered in yeast genetic studies as regulating lifespan, and these enzymes might be targeted by resveratrol, one of the components in red wine that has been linked to increased lifespan in humans. Therefore, a thorough understanding of HDACs is required, not merely for understanding the regulation of chromatin structure, gene regulation and protein function, but also because HDACs are intimately involved in normal and abnormal cellular processes that greatly impact human health. With the identification, isolation, cloning and functional characterization of 18 human HDACs (HDAC1- 11 and SIRT1-7) and many acetyltransferases in the past decade, the coming years will see a continued dramatic expansion in our knowledge of the biological roles of HDACs and protein acetylation. As the only conference dedicated to this field, this biannual meeting plays an essential role in bringing together approximately 44 basic and clinical scientist speakers to exchange information and develop new therapeutic avenues with approximately 120 participants from around the world. A primary objective is to transfer knowledge between basic academic researchers, clinical scientists, and pharmaceutical scientists to create efficiencies in understanding how they control human health and how these activities can be harnessed to fight a diverse slate of diseases. A second objective is to foster the development and interests of younger investigators to help support their career development. To accomplish these objectives, the meeting venue houses meeting space, dining, and rooms so that participants have ample time to move from formal presentations to informal brainstorming and collaborative discussions. In addition, the morning and evening oral presentation sessions include 2-3 talks from junior scientists selected from the submitted abstracts, which is important for career development and to encourage the next generation of HDAC scientists. There will be an emphasis through both the scientific and social programs on creating a global HDAC community. This meeting will be particularly timely because data from on a new generation of HDAC and Bromodomain drugs will be presented. Therefore, support is requested for the 4th biannual conference on the biology and therapeutic targeting of HDACs and Sirtuins, and their role in aging and disease to be held at Il Ciocco, Lucca, Italy, August 18-23, 2013 in conjunction with FASEB.